XML 239 R162.htm IDEA: XBRL DOCUMENT v3.26.1
Equity-settled share-based transactions - Schedule of ACT Genomics plan, Narrative (Details) - ACT genomics - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Disclosure of terms and conditions of share-based payment arrangement [line items]    
Weighted average exercise price of share options outstanding in share-based payment arrangement (in $ per share)   $ 0.01
Weighted average remaining contractual life of outstanding share options   9 years
Weighted average fair value at measurement date, share options granted   $ 0.33
Expense from equity-settled share-based payment transactions $ 1,226,000 $ 1,873,000
Bottom    
Disclosure of terms and conditions of share-based payment arrangement [line items]    
Vesting Period (in years) 2 years  
Top of range    
Disclosure of terms and conditions of share-based payment arrangement [line items]    
Vesting Period (in years) 3 years